RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
Introduction. The anthracycline antibiotics cause clinically significant manifestations of cardiotoxicity (СТ) – myocardial injuries, reducing both quality and life expectancy of the oncological patients.The purpose of the study was to evaluate the incidence and risk factors anthracycline-induced СТ...
Saved in:
| Main Authors: | N. T. Vatutin, E. V. Sklyannaya, M. A. El-Khatib, I. A. Sologub |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-10-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/255 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01) -
Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01) -
Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01) -
Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis
by: Runyu Liu, et al.
Published: (2025-07-01) -
The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)